ProPhase Labs, Inc. (NASDAQ:PRPH – Get Free Report) saw a large increase in short interest in January. As of January 15th, there was short interest totalling 116,400 shares, an increase of 19.1% from the December 31st total of 97,700 shares. Based on an average daily trading volume, of 290,200 shares, the days-to-cover ratio is currently 0.4 days.
Analyst Ratings Changes
Separately, StockNews.com began coverage on shares of ProPhase Labs in a report on Saturday. They issued a “sell” rating for the company.
Get Our Latest Stock Analysis on ProPhase Labs
Institutional Trading of ProPhase Labs
ProPhase Labs Stock Performance
Shares of PRPH stock opened at $0.26 on Monday. The company has a 50-day moving average of $0.65 and a two-hundred day moving average of $1.73. ProPhase Labs has a 1-year low of $0.26 and a 1-year high of $7.48. The company has a quick ratio of 1.33, a current ratio of 1.47 and a debt-to-equity ratio of 0.48.
ProPhase Labs Company Profile
ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.
Featured Articles
- Five stocks we like better than ProPhase Labs
- How to Use the MarketBeat Excel Dividend Calculator
- 3 Stocks to Gain From Trump’s Return-to-Office Mandate
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Crane Stock Soars, But the Best Could Be Yet to Come: Here’s Why
- Why Are Stock Sectors Important to Successful Investing?
- ServiceNow Stock Slips, But AI Expansion Signals Long-Term Gains
Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.